Blog
Unpacking Trump’s Drug Pricing Executive Order & the 2026 Part D...
8 Minute Read
This month, we offer commentary on two topics around Unpacking Part D Redesign in 2026 and Trump’s Drug Pricing Executive Order.
Optimizing Pharma Net Revenue Under New Market Dynamics
4 Minute Read
This year's Asembia conference was highly impactful, offering deep insights into pharmaceutical manufacturers' top challenges and future commercial data needs, particularly highlighting the growing demand for real-time, integrated data...
Bringing Clarity to the Complexities of Pharma Commercial Data at Asembia...
4 Minute Read
This year's Asembia conference was highly impactful, offering deep insights into pharmaceutical manufacturers' top challenges and future commercial data needs, particularly highlighting the growing demand for real-time, integrated data...
What MFN Pricing Initiatives Mean for Manufacturers: Key Insights from the...
3 Minute Read
May 20, 2025, the U.S. Department of Health and Human Services (HHS) issued a significant update on the Executive Order “Delivering Most Favored Nation Prescription Drug Pricing to...
Navigating Pharma Distribution Models: Insights from Industry Leaders Part 2
5 Minute Read
Part 2 of our blog examines how new distribution models and market access trends will impact future pharmaceutical strategy.
Direct-to-Patient & Fair Drug Pricing: Reshaping the Pharmacy Landscape
6 Minute Read
This month, we offer commentary on two topics around Direct-to-Patient and the Impact of Maximum Fair Prices on the First 10 Medicare-Negotiated Drugs.
2025 Branded Prescription Drug Fees Considerations
3 Minute Read
Keep up-to-date on Branded Prescription Drug Fees with this summary of critical insights from Nick Lynch, Partner at IntegriChain, covering key deadlines and factors.
Navigating the Impact of Policy Changes on Pharma Market Access: Insights...
4 Minute Read
The pharmaceutical industry is facing unprecedented challenges as market access dynamics continue to evolve. To navigate these complexities, companies must rethink channel, pricing, contracting, and patient access strategies.
Pharma Fair Market Value Strategies & Bona Fide Service Fees: 2024/2025...
4 Minute Read
In this blog, we recap the key insights shared by Nick Lynch, Partner at IntegriChain, and Suriya Janarthanan, Associate Director at Novartis, on how manufacturers can navigate FMV and...